{"title":"Immune-Therapy Standards Of Care","authors":"F. Griesinger","doi":"10.19080/ijoprs.2019.04.555633","DOIUrl":null,"url":null,"abstract":"Lung cancer ist the most frequent deadly malignant disease in men and the second most deadly malignant disease in women [1]. Two “leap†innovations, the detection of driver mutations in about 25% of patients and the observation that NSCLC is an immune-checkpoint-inhibitor responsive disease leading to a dramatic improvement in ORR, PFS and OS, therapeutic standards in NSCLC have changed dramatically over the past decade [2].","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"17 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pulmonary & Respiratory Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/ijoprs.2019.04.555633","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Lung cancer ist the most frequent deadly malignant disease in men and the second most deadly malignant disease in women [1]. Two “leap†innovations, the detection of driver mutations in about 25% of patients and the observation that NSCLC is an immune-checkpoint-inhibitor responsive disease leading to a dramatic improvement in ORR, PFS and OS, therapeutic standards in NSCLC have changed dramatically over the past decade [2].
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
